search
Back to results

Preventing Opioid Overdose Mortality in the United States

Primary Purpose

Opioid Overdose

Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Implementation Manual with External Facilitation Intervention
Implementation Manual only
Sponsored by
RTI International
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Opioid Overdose focused on measuring Opioid Overdose Prevention, Naloxone Implementation, Implementation Science

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • SSPs that participate in the on-line screening survey and fall into the implementation phase of the EPIS continuum will be recruited into the study.

Exclusion Criteria:

-

Sites / Locations

  • RTI InternationalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Implementation Manual and External Facilitation

Implementation Manual - only

Arm Description

This arm will receive the naloxone intervention implementation manual and the External Facilitation (EF) intervention. The manual provides details for developing, implementing, and managing a naloxone intervention program within different types of organizations that serve people who use opioids, including SSPs. The EF intervention is a collaborative, organization-centered form of guiding to navigate barriers and leverage facilitators to advance an evidence-based intervention along the EPIS continuum. Guidance will be conducted by an External Facilitator.

This arm will receive the naloxone intervention implementation manual. The manual provides details for developing, implementing, and managing a naloxone intervention program within different types of organizations that serve people who use opioids, including SSPs.

Outcomes

Primary Outcome Measures

Adoption of Best Practices
Number of Best Practices adopted by the SSP
Adoption of Best Practices
Number of Best Practices adopted by the SSP
Naloxone Coverage
Number of SSP participants receiving a dose of naloxone
Naloxone Coverage
Number of SSP participants receiving a dose of naloxone
Number of Naloxone Doses Distributed to SSP participants
Naloxone Dispensed
Number of Naloxone Doses Distributed to SSP participants
Naloxone Dispensed

Secondary Outcome Measures

Full Information

First Posted
April 19, 2019
Last Updated
September 15, 2020
Sponsor
RTI International
Collaborators
National Institute on Drug Abuse (NIDA)
search

1. Study Identification

Unique Protocol Identification Number
NCT03924505
Brief Title
Preventing Opioid Overdose Mortality in the United States
Official Title
Preventing Opioid Overdose Mortality in the United States
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Unknown status
Study Start Date
September 3, 2019 (Actual)
Primary Completion Date
September 2021 (Anticipated)
Study Completion Date
September 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
RTI International
Collaborators
National Institute on Drug Abuse (NIDA)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study aims to generate knowledge regarding the process of implementing naloxone within syringe service programs (SSPs), and to test whether external facilitation can improve implementation of naloxone within SSPs throughout the country. Together, these efforts can improve access to naloxone for people at high risk of overdose, thereby improving our nation's response to the opioid overdose epidemic.
Detailed Description
The purpose of this study is to understand and improve naloxone implementation within Syringe Service Programs (SSPs) to reduce opioid overdose mortality in the United States. To achieve this goal, we will implement an external facilitation intervention that has been shown to improve implementation in HIV service settings. The intervention will leverage a naloxone implementation expert who will work with SSP organizational directors to identify barriers to and facilitators of achieving naloxone implementation quality and maximizing reach. We propose to assess the effectiveness of external facilitation, compared to dissemination of an implementation manual, in a national sample of SSPs in a randomized controlled trial (RCT). Our proposed specific aims are as follows: Aim 1: To characterize United States syringe service programs along the exploration, preparation, implementation and sustainment (EPIS) continuum for delivering naloxone. Aim 2: To test the effectiveness of external facilitation + dissemination of the naloxone implementation manual, compared with dissemination of the naloxone implementation manual alone, to improve the advancement of naloxone along the EPIS continuum among United States syringe service programs. Hypothesis. The dissemination and external facilitation arm will be more effective in advancing naloxone implementation along the EPIS continuum between baseline and 12-month follow-up, than the dissemination-only arm. To achieve these aims, 425 SSPs that are registered with the North American Syringe Exchange Network (NASEN) and /or receive information from harm reduction related web-based forums (e.g., online discussion groups, newsletters and listservs)will be asked to participate in an on-line cross-sectional survey and will be sent a hyperlink to the initial screening survey. We will use the on-line survey results to characterize the SSPs along the exploration, preparation, implementation and sustainment (EPIS) continuum for delivering the naloxone intervention (AIM 1). The on-line survey includes a set of questions designed to collect information to evaluate where the SSP falls along the EPIS continuum for naloxone delivery. SSPs in the Implementation (I) phase of the EPIS continuum (estimated n = 100) will be contacted by research staff and offered the opportunity to participate in the RCT. SSPs that are interested in participating in the RCT will be enrolled in the study. For those SSPs who agree to participate, study staff will confirm eligibility by reviewing and documenting responses to the screening survey. Following informed consent procedures, the study staff will administer the baseline survey to the SSP representative. The baseline survey will include questions about programmatic capacity, organizational culture, potential for internal champion or leader, perceived need for naloxone distribution within their community, and community acceptance of peer naloxone distribution programming. The study staff will then randomize SSPs into one of the one of the two study arms: (1) dissemination of the implementation manual and external facilitation for 12 months (experimental arm; n=50) and (2) dissemination of the implementation manual only (control arm; n=50). All SSPs enrolled in the RCT will be sent a copy of the naloxone implementation manual either via email, hyperlink or the U.S. postal service depending on the preference of the participant. Those SSPs in the experimental arm will be enrolled in the EF intervention during which they will work directly with an OC to advance naloxone delivery as far along the EPIS continuum as possible during a 12-month period. The intervention will be delivered via phone calls, web-enabled audio and screen-sharing technology, and site visits. The key activities of the EF intervention include, initial SSP engagement, knowledge enhancement, capacity assessment, information gathering, identification of barriers and facilitators, development of action plans and provision of feedback, identification of funding and linkage to resources, and training of SSP staff. At the end of the 12-month intervention period, SSPs in both study arms will participate in a follow-up survey, conducted by study staff, to evaluate advancement of naloxone implementation along the EPIS continuum.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Opioid Overdose
Keywords
Opioid Overdose Prevention, Naloxone Implementation, Implementation Science

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Implementation Manual and External Facilitation
Arm Type
Experimental
Arm Description
This arm will receive the naloxone intervention implementation manual and the External Facilitation (EF) intervention. The manual provides details for developing, implementing, and managing a naloxone intervention program within different types of organizations that serve people who use opioids, including SSPs. The EF intervention is a collaborative, organization-centered form of guiding to navigate barriers and leverage facilitators to advance an evidence-based intervention along the EPIS continuum. Guidance will be conducted by an External Facilitator.
Arm Title
Implementation Manual - only
Arm Type
Active Comparator
Arm Description
This arm will receive the naloxone intervention implementation manual. The manual provides details for developing, implementing, and managing a naloxone intervention program within different types of organizations that serve people who use opioids, including SSPs.
Intervention Type
Behavioral
Intervention Name(s)
Implementation Manual with External Facilitation Intervention
Intervention Description
Participating organizations will receive the implementation manual and the external facilitation (EF) intervention. The manual provides instructions for organizations wanting to implement a high quality naloxone program. The EF will assist syringe service programs to integrate naloxone delivery within their organization. As part of these efforts, we will use a measurement framework to understand naloxone delivery within SSPs along the four phases of the implementation process-exploration, preparation, implementation and sustainment (EPIS).
Intervention Type
Behavioral
Intervention Name(s)
Implementation Manual only
Intervention Description
Participating organizations will receive the implementation manual.The manual provides instructions for organizations wanting to implement a high quality naloxone program.
Primary Outcome Measure Information:
Title
Adoption of Best Practices
Description
Number of Best Practices adopted by the SSP
Time Frame
Baseline
Title
Adoption of Best Practices
Description
Number of Best Practices adopted by the SSP
Time Frame
12 months
Title
Naloxone Coverage
Description
Number of SSP participants receiving a dose of naloxone
Time Frame
Baseline
Title
Naloxone Coverage
Description
Number of SSP participants receiving a dose of naloxone
Time Frame
12 months
Title
Number of Naloxone Doses Distributed to SSP participants
Description
Naloxone Dispensed
Time Frame
Baseline
Title
Number of Naloxone Doses Distributed to SSP participants
Description
Naloxone Dispensed
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: SSPs that participate in the on-line screening survey and fall into the implementation phase of the EPIS continuum will be recruited into the study. Exclusion Criteria: -
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Barrot Lambdin, PhD, MPH
Phone
510-665-8254
Email
blambdin@rti.org
First Name & Middle Initial & Last Name or Official Title & Degree
Lynn Wenger
Phone
510-665-8219
Email
lynndee@rti.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Barrot Lambdin, PhD, MPH
Organizational Affiliation
RTI International
Official's Role
Principal Investigator
Facility Information:
Facility Name
RTI International
City
Berkeley
State/Province
California
ZIP/Postal Code
94704
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Barrot Lambdin, PhD, MPH
Phone
510-665-8254
Email
blambdin@rti.org
First Name & Middle Initial & Last Name & Degree
Lynn D Wenger, MSW, MPH
Phone
510-665-8219
Email
lynndee@rti.org

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Preventing Opioid Overdose Mortality in the United States

We'll reach out to this number within 24 hrs